Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07177482
Recruiting Not applicable

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients

NCT07177482 · tracked via the Priya Life Science China tracker
Sponsor
Deling Li
Phase
Not applicable
Started
2025-07-04
Last updated
2025-09-17

Condition(s) studied

Craniopharyngioma

Investigational drug(s) / intervention(s)

68Ga-MY6349 PET/CT

68Ga-MY6349 PET/CT: Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.

Study summary

This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.

Eligibility

Sex
ALL
Min age
14 Years
Max age
80 Years
Healthy volunteers
No
Inclusion criteria: * must be able to provide a written informed consent * radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection * adequate clinical condition (Karnofsky performance status ≥70) Exclusion criteria: * concomitant major central nervous system disorders * severe hepatic or renal dysfunction * history of severe allergy or hypersensitivity to intravenous radiographic contrast agents * claustrophobia precluding PET/CT or MRI examinations * pregnancy or breastfeeding

Primary outcome measure(s)

  • Standardized uptake value of 68Ga-MY6349 in PET imaging of craniopharyngioma — Within 1 week after PET imaging.
    The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in craniopharyngioma will be measured.

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing Beijing Municipality Recruiting

Other trials for the same condition

China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm Active, not recruiting
Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07177482 on ClinicalTrials.gov ↗ ← All trials in China